Cardiovascular outcome trials show that treatment with long-acting GLP-1 medicines such as liraglutide, dulaglutide, and semaglutide reduces cardiovascular events in people living with T2D and with semaglutide also in people living with obesity (60–62). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.